精氨酸脱氨酶
医学
药品
精氨酸
药理学
肝细胞癌
PEG比率
内科学
化学
生物化学
氨基酸
财务
经济
作者
Li-Jiuan Shen,Wei‐Chiang Shen
出处
期刊:PubMed
日期:2006-06-01
卷期号:8 (3): 240-8
被引量:12
摘要
Pheonix is developing ADI-PEG-20, a PEGylated arginine deiminase for the potential treatment of hepatocellular carcinoma, for which the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products have granted the drug Orphan Drug status, and melanoma, for which the FDA has also awarded ADI-PEG-20 Orphan Drug status. ADI-PEG-20 is also being investigated for the potential treatment of influenza virus infection and hepatitis C virus infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI